LOGIN  |  REGISTER
Terns Pharmaceuticals

CareDx to Participate in the Raymond James & Associates’ 45th Annual Institutional Investors Conference

February 27, 2024 | Last Trade: US$16.85 0.26 -1.52

BRISBANE, Calif. / Feb 27, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the company will be participating in the upcoming Raymond James & Associates’ 45th Annual Institutional Investors Conference.

CareDx’s management is scheduled to present on Wednesday, March 6, 2024, at 9:50 a.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the “Investors” section of the company’s website at investors.CareDx.com.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit www.CareDx.com.

C4 Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page